The incidence of grade ≥2 cytokine release syndrome was lower in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a B-cell maturation antigen-targeted CAR T-cell therapy.
Recent Content
- Immuno-gene therapy for brain cancer tumors now on FDA fast track
- Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia
- FDA approves Keytruda for hard-to-treat gynecological cancers
- Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients
- FDA reviewing new iberdomide combo for hard-to-treat multiple myeloma
- (no title)
- FDA approves all-oral combo therapy for previously untreated CLL
- Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
- Pancreatic cancer growth tied to cells’ self-eating process
- Telix seeks European approval of glioma imaging agent